Case Report

Autoimmune Progesterone Dermatitis: A Case Report

Rachana George and Shawky Z. A. Badawy

Department of Obstetrics and Gynecology, Upstate Medical University, Syracuse, NY 13210, USA

Correspondence should be addressed to Shawky Z. A. Badawy, badawys@upstate.edu

Received 25 June 2012; Accepted 19 July 2012

Copyright © 2012 R. George and S. Z. A. Badawy. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Autoimmune progesterone dermatitis is a rare disease caused by an autoimmune response to endogenous progesterone in women during their reproductive years [1]. Skin lesions typically occur due to increases in progesterone during the luteal phase of the menstrual cycle [2]. It was first described in 1921 [1].

2. Case Report

A thirty-eight-year-old married Caucasian female was referred to our reproductive endocrinology clinic by her gynecologist secondary to cyclical urticaria. Patient has a gynecologic history of menarche at the age of 12 and reports 28 day menstrual cycles. Patient states she gets an erythema multiforme, urticaria, angioedema, and progesterone-induced anaphylaxis. Case. Thirty-eight-year-old woman G2P2002 presents with erythema multiforme and urticarial rash one week prior to her menses starting one year after menarche. She was treated with oral contraceptive pills and the symptoms resolved. Conclusion. This is a typical case of progesterone autoimmunity. The diagnosis is based on cyclic nature of the dermatitis. This differentiates the condition from other allergies or systemic diseases with skin manifestations. Inhibition of ovulation in such cases results in decrease in progesterone secretion and prevention of symptoms.

3. Comments

Autoimmune progesterone dermatitis is a rare condition that occurs during the second half of the menstrual cycle. Dermatological symptoms include urticaria, eczema, angioedema, deep gyrate lesions, papulovesicular lesions, targetoid lesions, or anaphylaxis. Symptoms usually occur three to ten days prior to the onset of menstrual flow and resolve 2 days into menses [5]. Symptoms of autoimmune progesterone dermatitis correlate with progesterone levels during the luteal phase of the menstrual cycle [3, 4]. Patient
clinical presentation can vary in severity from mild urticaria to anaphylaxis [5, 6].

The onset of autoimmune progesterone dermatitis is variable. The earliest age reported has been at menarche [7]. Diagnosis is made with appropriate clinical history as well as confirmation with intradermal progesterone skin injections [6]. An aqueous suspension or aqueous alcohol solution of progesterone is the preferred agent of testing as it is less likely to cause an irritant reaction compared to progesterone in oil [6]. The skin reaction may be seen immediate within half an hour or delayed up to 48 hours.

There are some disorders similar to autoimmune progesterone dermatitis. One in particular that should be considered when evaluating a patient is mastocytosis. Mastocytosis is a group of disorders characterized by excessive mast cell accumulation in one or multiple tissues. It is subdivided into two groups. One group is cutaneous mastocytosis which is limited to the skin. The second group is systemic mastocytosis where mast cells infiltrate extracutaneous organs. The typical presentation for mastocytosis is pruritus, epigastric pain, nausea, vomiting, chronic diarrhea, and arthralgias. It can also present at neuropsychiatric changes such as irritability, depression, and mood liability. Patients may also have hepatic and splenic infiltration that may cause portal hypertension resulting in ascites. One cutaneous manifestation of mastocytosis occurs when the patient strokes or rubs their skin and it causes urticaria and erythema around lesions known as Darier’s sign. Systemic symptoms can occur in any form but the most common is flushing. The most dramatic symptom is anaphylaxis with syncope or even shock. The symptoms of mastocytosis are not cyclic.

Pregnancy can impact the symptomatology of autoimmune progesterone dermatitis. The increase of maternal progesterone during pregnancy may improve the disease process. Our patient experienced resolution of symptoms during pregnancy. The gradual rise of progesterone during pregnancy may act as a desensitizing agent, ultimately reducing symptoms. Due to increased production of anti-inflammatory glucocorticoids during pregnancy, the decrease in maternal immune response may also play a role in improving symptoms. In addition, autoimmune progesterone dermatitis during pregnancy has been associated with spontaneous abortions [1, 6, 8]. Wojnarowska reported as case of a women who became pregnant, developed erythema multiforme at five weeks of gestation, and had a spontaneous abortion at 10 weeks [8].

Treatment of autoimmune progesterone dermatitis is achieved mainly through suppressing ovulation. The first line of therapy is combined oral contraceptives. The use of GnRH agonists has been reported successful in treatment [6]. Another therapeutic agent used to suppress ovulation and improve symptoms is tamoxifen [6]. Danazol has also been reported successful in treating autoimmune progesterone dermatitis [7]. Autoimmune progesterone dermatitis has been shown to be resistant to antihistamine therapy, as displayed in our patient [6]. For patients who experience unremitting symptoms after medical management, bilateral oophorectomy is recommended [9].

References

[1] J. Gerber, “Desensitization in the treatment of menstrual intoxication and other allergic symptoms,” British Journal of Dermatology, vol. 51, pp. 265–268, 1930.
[2] J. L. Snyder and G. Krishnaswamy, “Autoimmune progesterone dermatitis and its manifestation as anaphylaxis: a case report and literature review,” Annals of Allergy, Asthma and Immunology, vol. 90, no. 5, pp. 469–477, 2003.
[3] W. N. Jones and V. H. Gordon, “Auto-immune progesterone eczema. An endogenous progesterone hypersensitivity,” Archives of Dermatology, vol. 99, no. 1, pp. 57–59, 1969.
[4] S. M. Wilkinson, M. H. Beck, and T. P. Kingston, “Progesterone-induced urticaria—need it be autoimmune?” British Journal of Dermatology, vol. 133, no. 5, pp. 792–794, 1995.
[5] M. Burstein, A. Rubinow, and M. Shalit, “Cyclic anaphylaxis associated with menstruation,” Annals of Allergy, vol. 66, no. 1, pp. 36–38, 1991.
[6] A. P. Baptist and J. L. Baldwin, “Autoimmune progesterone dermatitis in a patient with endometriosis: case report and review of the literature,” Clinical and Molecular Allergy, vol. 2, article no. 10, 2004.
[7] F. S. Farah and Z. Shbaklu, “Autoimmune progesterone urticaria,” The Journal of Allergy and Clinical Immunology, vol. 48, no. 5, pp. 257–261, 1971.
[8] F. Wojnarowska, M. W. Greaves, and R. D. G. Peachey, “Progesterone-induced erythema multiforme,” Journal of the Royal Society of Medicine, vol. 78, no. 5, pp. 407–408, 1985.
[9] J. M. Rodenas, M. T. Herranz, and J. Tercedor, “Autoimmune progesterone dermatitis: treatment with oophorectomy,” British Journal of Dermatology, vol. 139, no. 3, pp. 508–511, 1998.